RecruitingEarly Phase 1
Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.
NCT07732166 · Pontifícia Universidade Católica do Rio de Janeiro
Recruiting
Status
Accepting participants
Early Phase 1
Phase
100
Target enrolment
1
Study sites
Outside the US
What it is testing
Summary
Self-awareness, the capacity of becoming the object of one's own awareness, is a frontier of scientific knowledge. Over centuries, distinct philosophical and religious traditions have grappled with the subject, but only recently has the importance of self-awareness been established as a central concept for scientific investigation, to which scientific methods can be applied to explore and characterize this phenomenon. Self-awareness has important implications, notably from a clinical perspective. Psychedelics can affect the sense of self, with 'ego dissolution' being an essential feature of the experience of substances such as psilocybin and dimethyltryptamine. Recent evidence indicates that psychedelics can rearrange brain connectivity, with these changes being linked to alterations in self-awareness. Nevertheless, the extent to which specific components of self-awareness are modified by these substances has not been fully explored. It is possible that part of the clinical benefits of psychedelics, for conditions such as depression, OCD, and anxiety, is mediated by changes in self-awareness. Given this clinical potential, the current study aims to examine the effects of psilocybin on various components of self-awareness in healthy participants. 100 participants will be allocated to receive either 15mg of psilocybin (n=50) or an active placebo (100mg niacin; n=50). Participants will be assessed one week before, immediately after, and one week after the administration of the substances, performing tasks and completing questionnaires measuring self-awareness at these time points. The neural correlates of self-awareness, before and after substance effects, will be investigated using near-infrared spectroscopy. Participants allocated to the placebo group will be invited to an open-label extension with psilocybin upon availability of the substance. It is expected that the results of the study will elucidate the brain regions involved in self-awareness, as well as the alterations induced by psilocybin in this process, opening the possibility of new therapeutic interventions for different clinical groups.
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Changes in global metacognitive judgment using the Computerized Success-Failure Manipulation Paradigm.
Measured over From baseline (one week before the dosing session) to follow up (one week after the dosing session).
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
21 Years to 60 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria:
* Minimum age of 21 and maximum age of 60;
* Minimum of eight years of schooling;
* Fluency in Portuguese;
* Agree, one week before the experiment, to abstain from:
* Using any herbal supplements (except with prior approval from the researchers);
* Using any non-prescribed medication (except non-steroidal anti-inflammatory drugs or paracetamol, provided they have prior approval from the research team);
* Using any prescribed medication (except birth control pills, thyroid hormones, or other medications, provided they have prior approval from the research team);
* Using recreational psychoactive substances;
* Agree to abstain, 24 hours before the experiment, from:
* Consuming beverages with high caffeine content (e.g., coffee, mate, cola);
* Consuming alcoholic beverages;
* Agreeing not to use caffeine or nicotine for two and six hours, respectively, after the experiment;
* Agree not to drive a motor vehicle or operate machinery for 24 hours after the experiment;
* Be available to be contacted by telephone for all planned stages;
* Agree to use effective contraception throughout the study;
* Agree to inform researchers of any medical condition or procedure that may arise prior to the experiment;
* Agree not to participate in any other interventional clinical trial for the duration of this study.
Exclusion Criteria:
* History of traumatic brain injury, stroke, epilepsy, neurological disease, or cardiovascular disease;
* Evidence or history of coronary or cerebral artery disease, peripheral vascular disease, liver disease with altered liver enzymes, or any other medical condition that the researchers, including the responsible physician, deem to significantly increase the risk of administering any substance;
* Pregnant or breastfeeding women, or women who could potentially become pregnant and are not using any effective contraceptive method;
* Women who, at the screening stage, do not have a negative pregnancy test.
* Having a history of or currently having a primary psychotic disorder, schizophrenia spectrum disorder, bipolar affective disorder (type 1 and 2), dissociative identity disorder, major depressive disorder;
* History of psychotic disorders in a first-degree relative;
* Have resting blood pressure that does not exceed 140 mmHg (systolic) and 90 mmHg (diastolic) - measured in four assessments on at least two different days;
* Have resting blood pressure below 90 mmHg (systolic) and 60 mmHg (diastolic) - measured in four assessments on at least two different days;
* Weigh less than 48 kg;
* Require therapy with psychiatric medications concurrently with the study;
* Have a history of or present with gastrointestinal disease;
* Previous use of psilocybin or similar substances;
* Frequent use (at least once a month) of any other psychoactive substance in the last year, except for nicotine, caffeine and alcohol;
* Have a history of disorders or problems related to the use of psychoactive substances;
* Not be able to provide adequate informed consent;
* Any other condition that may compromise the results or that represents any risk to the participant, according to the assessment of the research team and the responsible physician.
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Centro de Pesquisas Matteo Ricci | Rio de Janeiro | Rio de Janeiro | Brazil |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT07732166 on ClinicalTrials.gov →
Last updated in the registry 2026-07-28. Registry records change; this page reflects the data build of 2026-08-25.
Related
Where this trial sits
Substance